GoKawiilInsilico's AI-designed lung drug rentosertib shows anti-aging signals in trial
Insilico Medicine's AI-designed drug rentosertib, originally developed to treat idiopathic pulmonary fibrosis, produced unexpected reductions in biological age markers during a phase 2a trial. Researchers reanalyzed blood samples from 42 of 71 Chinese trial participants using six computational aging clocks, finding treated patients showed younger predicted ages after 12 weeks compared to placebo recipients.
GoKawiil's interpretation of the reporting above, not reported fact.
This is one of the first times an AI-discovered drug has shown measurable anti-aging effects in human trial data, even though it wasn't designed for that purpose. However, since all participants had lung disease, scientists can't yet tell whether the anti-aging signal reflects a true biological effect or simply improvement from treating the underlying illness, meaning broader anti-aging claims remain unproven.
- Rentosertib, an AI-designed drug for pulmonary fibrosis, showed signs of lowering biological age in a small trial.
- Six different aging clock models detected younger predicted ages in treated patients versus placebo.
- Researchers caution the effect might stem from lung disease improvement rather than a general anti-aging mechanism, requiring further study.
Source: techspot.com — Rob Thubron, 2026-09-08
Published there as: “An AI-developed drug appeared to make patients biologically younger in a clinical trial”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.